Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 32Recurrence 8Neoplasms 6Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Smoldering Multiple Myeloma 1Sarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoma, Small Cell 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Dexamethasone 3Calcium Dobesilate 3Melphalan 2venetoclax 1pomalidomide 1Thalidomide 1Surveys and Questionnaires 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Amyloidosis × pomalidomide × Clear all
NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Plasma cell

Amyloidosis, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡